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Introduction: Confinement of biomolecules in structured nanoporous materi-
als offers several desirable features ranging from chemical and thermal stabil-
ity, to resistance to degradation from the external environment. A new
generation of mesoporous materials presents exciting new possibilities for
the formulation and controlled release of biological agents. Such materials
address niche applications in enteral and parenteral delivery of biologics,
such as peptides, polypeptides, enzymes and proteins for use as therapeutics,
imaging agents, biosensors, and adjuvants.
Areas covered: Mesoporous silica Santa Barbara Amorphous-15 (SBA-15), with
its unique, tunable pore diameter, and easily functionalized surface, provides
a representative example of this new generation of materials. Here, we
review recent advances in the design and synthesis of nanostructured
mesoporous materials, focusing on SBA-15, and highlight opportunities for
the delivery of biological agents to various organ and tissue compartments.
Expert opinion: The SBA-15 platform provides a delivery carrier that is inher-
ently separated from the active biologic due to distinct intra and extra-
particle environments. This permits the SBA-15 platform to not require direct
modification of the active biological therapeutic. Additionally, this makes the
platform universal and allows for its application independent of the desired
methods of discovery and development. The SBA-15 platform also directly
addresses issues of targeted delivery and controlled release, although future
challenges in the implementation of this platform reside in particle design,
biocompatibility, and the tunability of the internal and external material
properties. Examples illustrating the flexibility in the application of the
SBA-15 platform are also discussed.
Keywords: compartmentalization, confinement, controlled release, drug delivery,
extra-particle effects, intra-particle effects, MCM-41, mesoporous silica, nanoparticle
therapeutics, protein therapeutics, SBA-15, targeted delivery
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1. Introduction
The last few decades have brought significant advances in the design and synthesis
of novel drug delivery systems [1-4]. These advances have focused on addressing crit-
ical challenges in improving systemic stability of drugs; designing better formulation
strategies for drugs; achieving cell-, tissue- or organ-specific targeting; and providing
controlled release of the active drug at the site of interest. These advances have
collectively contributed to improved delivery systems and superior clinical outcomes
in patients [5,6].
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.A systematic trend in drug development during the last two
decades is the shift towards biologics [7]. Biologics comprise a
broad range of molecules that are typically large molecular
weight drugs, which include peptides, polypeptides, proteins,
antibodies and enzymes. Biologics provide improved thera-
peutic end points when compared with small-molecule drugs
in terms of efficacy, selectivity and targeting. However, they
are limited by poor systemic and oral stability, are prone to
proteolytic degradation and show high susceptibility to tem-
perature and chemical agents [8]. Therefore, enhancing the sta-
bility and bioavailability of biologics in the physiological
environment is critical for their therapeutic success.
Recent studies [9], including those from our group [10],
demonstrate that confinement of biomolecules in nanostruc-
tured porous materials, with uniform pores slightly wider
than the biomolecule, can significantly enhance molecular
stability to proteases, temperature and solution conditions.
Although this work bears certain similarities to prior work
that has evaluated the effects of immobilisation on non-
porous nanoparticles [11], confinement of biomolecules in
nanoporous materials is fundamentally different. The key
difference that changes the fundamental behaviour between
confinement on the internal surface of porous materials and
external surface adsorption is that porous, nanostructured
materials inherently provide separate internal and external
environments. This is due to the physical differences between
the environments, including solvent effects, and surface
proximity and chemistry. It follows that the interactions of
the confined biomolecules with their environment are also
inherently distinct. This affords greater design flexibility by
decoupling considerations for the biomolecular cargo and
the physiological environment. For this reason, many porous
materials are currently being investigated for drug delivery
applications, such as zeolites [12], mesoporous carbons [13],
mesoporous silicas [14,15], metal organic frameworks [16,17],
hydrogels [18], micelles [3] and calcium phosphate cements [19].
Although many of these materials show great promise, they
also tend to either be sensitive to the external environment
as a whole or are difficult to engineer internally. Material
sensitivity to the environment can range from pH and ionic
strength considerations, to general chemical instability and
enzymatically mediated decomposition. Difficulties of inter-
nal engineering can be due to the dependence of internal
properties on the synthetic steps required for tuning of the
external properties or the lack of ability to tune the internal
surface chemistry, porosity or tortuosity. For these reasons,
many of these materials are not necessarily the best candidates
for drug delivery. In contrast, a relatively new class of ordered
mesoporous silica particles provides a promising framework
that has broad flexibility in its chemical and structural features
at multiple (~ 2n mt o1µm) length scales. In this expert
opinion, we focus on recent advances regarding a compelling
mesoporous silica candidate that fits this niche, Santa Barbara
Amorphous-15 (SBA-15) [20].
2. Current limitations of nanomaterials in
drug delivery
Before evaluating any novel nanomaterial candidate for drug
delivery, it is important to first evaluate where current materi-
als fall short. Key properties that are desired in a nanomaterial
candidate include selective compartmental distribution in
organs and tissues, particle size uniformity, selective affinity-
based interactions, material stability and biodegradability,
versatile surface chemistry and tunable particle geometry [21].
For example, the small size (20 -- 100 nm) of nanoparticles
provides the perfect advantage due to enhanced permeability
and retention (EPR) [22] in tumours because of increased
porosity of the adjacent vasculature. This leads to non-
specific, but selective biodistribution in tumours [23]. EPR
has shown promise for drug delivery since the 1980s, but is
still significantly limited due to heterogeneity of the effect in
different tumours [23]. EPR is only one example of how the
control of particle size is advantageous as it relies on the link
between particle size, therapeutic effect and mechanism of
action. However, as the mechanism of EPR is governed pri-
marily by one parameter, cut-off size, this severely limits its
application as a method of drug delivery. This illustrates the
need for the next key property, particle size uniformity, which
is also important in the specific targeting of tumorous tissues.
Fenestrations in the vascular endothelium of pathological tis-
sues allow for the easy transport of nanoparticles to the desired
tissue, although this is complicated by the fact that fenestra-
tions vary greatly in size, from ~ 1 nm to 1.4 µm, depending
on the tissue [24]. If the size of the therapeutic nanoparticle can
be tuned to that of the fenestrations in the targeted tissue,
then the nanoparticle may be guided to the desired tumour
cells. Furthermore, the size and shape of a nanoparticle can
dramatically change how it interacts with the physiological
environment by limiting or mediating transport across mem-
branes, and regulating persistence in circulation or clearance
by the immune system [25-27]. With this in mind, if particle
size and shape uniformity cannot be ensured, neither can
the specificity of the nanoparticle’s interactions. Charge pro-
vides another design variable that can change the behaviour
of nanoparticles in physiological environments. Charge can
Article highlights.
. Confinement of biological therapeutics in porous
materials enables the inherently distinct intra and
extra-particle environments to be leveraged during the
therapeutic design process.
. SBA-15 allows independent tuning of key material
parameters.
. The SBA-15 platform allows for the delivery of protein
therapeutics without direct modification of the desired
therapeutic.
This box summarizes key points contained in the article.
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.be used to promote specific and desirable interactions. For
example, cationic nanoparticles have a higher internalisation
rate due to their electrostatic attraction with the negative
charge of cell membrane lipids [28]. However, electrostatic
charge can also promote non-specific interactions and lead
to non-specific distribution of particles, in addition to tar-
geted tissues [29]. As such, the ideal charge for a particle
depends on the desired application. Although no steadfast
rules for the desired particle charge apply, fewer non-specific
electrostatic interactions occur when the surface charge of a
particle is lower.
Due to shortcomings of some synthetic nanoparticles,
many researchers are also investigating the use of nanopar-
ticles synthesised of biological materials. These materials
usually consist of DNA [30], RNA [31], proteins [32], lipids [33]
and carbohydrates [34,35]. Such materials can provide several
advantages such as a high-packing density, which can lead to
enhanced dosing, an increased flexibility of design as these
materials naturally interact biologically and a lack of void vol-
ume as whole particles can be designed to be active. However,
such nanoparticles have their own set of complications [36,37].
These complications can include the requirement for additives
(such as trehalose) [38] and for conjugation or modification
unique to the specific nanoparticle [39]. In addition, biological
machinery is more apt to lead to undesired biological
responses and possible instability [40]. This is due to the
physiological familiarity of these materials, which can facili-
tate immunogenic response, lead to material degradation or
unexpectedly initiate signalling pathways. This is well illus-
trated by the two major hurdles of siRNA therapeutic candi-
dates: immunogenic response stimulated by the activation of
an undesired signalling pathway, and degradation in serum
due to the presence of ribonucleases [41].
As described previously, it is difficult to tune the specific
propertiesofmanynanoparticlesunderdevelopmentinaman-
ner that facilitates the desired biological response. Changing
one desired property might change another one that is equally
desirable for an application [42]. For example, altering the
synthesis procedure to tune the interactions of a hydrogel
with the physiological environment is likely to additionally
modulate the structural properties of the hydrogel and the
therapeutic--hydrogel interactions. This could result in signifi-
cant attenuation of desired therapeutic--hydrogel interactions.
Another example would be the chemical functionalisation of
liposome-based particles. Although functional groups can be
added, they must not significantly disrupt the defining lipid
bilayer and must follow the general rules of partitioning
between the hydrophilic and lipophilic phases. For nanopar-
ticles with desirable material properties, one approach to
address this shortcoming is to decouple particle--therapeutic
and particle--physiological interactions. This separation can
be achieved through the use of porous materials with proper-
ties that can be fine-tuned with near-atomic resolution [43],
such asSBA-15.Wewill reviewthesematerialsingreaterdetail
subsequently in this review.
3. A compelling nanoparticle candidate
An ideal nanoporous material for drug delivery would address
many of the challenges highlighted previously. Porous
materials with biomolecules confined in the pores allow for
separation of particle--biomolecule and particle--physiological
interactions to the interior and exterior of a particle, respec-
tively. The pore sizes that allow for the separation of these
interactions for protein biologics are typically in the mesopo-
rous range (2 -- 50 nm pore diameter). Challenges of engi-
neering the interface between the internal pore environment
and the biomolecule include issues such as proteolysis, pH
induced aggregation, shear induced denaturing, hydrophobic
denaturing and the regulation of biomolecular diffusion [44].
Although protection from proteolytic cleavage and pH-
induced aggregation is essential for almost all biological ther-
apeutics, it is particularly important for therapeutics that are
orally administered due to the high presence of proteases
and the variability of pH (1.5 -- 6.5) in the gastrointestinal
tract [45,46]. The combination of these two issues is one of
the major hurdles for oral delivery in biological therapeutics.
As the use of porous materials isolates particle--therapeutic
interactions to the interior of the particle, the extra particle
challenges deal primarily with the physiological interactions
of the particle and global targeting of the therapeutic. Extra
particle challenges include targeted delivery of the therapeutic,
isolation of particles, crossing of desired barriers and mitiga-
tion of non-discriminant interactions with proteins and
biomolecules in serum and other biological fluids. It is essen-
tial for each of these challenges to be addressed to localise
the therapeutic effect, minimise toxicity issues and achieve
effective therapeutic delivery.
There are several classes of porous nanoparticles currently
being investigated to address challenges in therapeutic deliv-
ery. These include polymeric gels [47], mesoporous carbon
[48], and mesoporous silica [49]. Each type of these materials
has its advantages and disadvantages. It is easy to synthesise
and control the degradation of polymeric gels, but the
pore size distribution and pore environment are difficult to
control [42]. Mesoporous carbons and silicas have well-
characterised synthesis methods and chemistry, but form
persistent rigid structures in physiological conditions [50,51].
Although this ensures particle stability, it also makes particle
clearance and accumulation a significant concern that must
be addressed during the therapeutic design phase. Out of
the possible classes of porous nanoparticles that would be
well suited for biological therapeutic delivery, mesoporous
silica SBA-15 presents a compelling candidate.
4. Nanoparticle candidate SBA-15
SBA-15isamesoporoussilicainwhichtheporesaretemplated
by tri-block copolymer micelles [20]. The material contains
hexagonally ordered cylindrical mesopores in one dimension,
Packaging biological cargoes in mesoporous materials
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.ranging from 5 to 15 nm in diameter with a very narrow pore
size distribution (< 2 nm fwhm) [52].The surface is hydrophilic
and weakly negatively charged (< -0.08 C/m
2) [53] under phys-
iological conditions. The internal and external surfaces of
SBA-15 provide easily accessible silanol groups that can be
functionalised through the use of silane chemistry, thereby
providing an avenue to modify the surface chemistry.
SBA-15 is synthesised by first dissolving Pluronic 123
(P123)tri-blockcopolymer(EO20PO70EO20,whereEOiseth-
ylene oxide and PO is propylene oxide) in an acidic aqueous
environment. Acidic, high-ionic strength P123 micelles trans-
form from spherical to cylindrical when tetraethyl orthosilicate
is added to the solution [54,55], which hydrolyses into silica
precursors and ethanol; the released ethanol increases the rate
ofself-assembly ofthecylindricalmicelles andthepolymerising
silica over the course of several hours, gradually leading up to a
composite consisting of hexagonally ordered cylindrical
micelles of P123, surrounded by a continuous silica phase.
This transformation continues via hydrothermal aging in an
oven. The temperature of the hydrothermal aging determines
the diameter of the cylindrical micelles, and, ultimately, the
pore diameter. Depending on the process conditions (stirring
rate, presence of inorganic salts, pH, temperature, etc.), materi-
als in a variety of shapes can be produced, such as particles,
fibres and films [56-59]. For example, minimal stirring promotes
the formation of monodispersed, approximately micron-sized
rods, with a width of a few hundred nanometres [60,61].
Subsequently, samples are washed, dried and the P123
template is removed by either calcination or solvent extrac-
tion [52,61]. If calcination is used to remove the template, son-
ication is often used to disperse the particles homogenously in
solution prior to further processing [62]. The two main ave-
nues to functionalise the surface of SBA-15 are surface graft-
ing and co-condensation. Surface grafting is very attractive
due to chemical flexibility and ability for complete coverage
of the functionalised surface [43]. On the other hand,
co-condensation is completed during the hydrolysis step of
the synthesis; hence, it can interfere with the structural
integrity of the synthesised particles. Regardless of the func-
tionalisation method implemented, Fourier transform infra-
red spectroscopy (FTIR) and nuclear magnetic resonance
spectroscopy, among other spectroscopic tools, can be used
to analyse the surface chemistry.
Typical characterisation of SBA-15 includes a combination
of analysis methods that characterise both the particle and the
pore structure [20]. These methods include gas sorption analy-
sis, x-ray diffraction or small angle x-ray scattering (SAXS),
and imaging via field emission scanning and high-resolution
transmission electron microscopy (FE-SEM and HRTEM)
[10]. An example is shown in Figure 1. The nitrogen adsorption
analysis shows a narrow pore size distribution around an aver-
age pore size of 5.9 nm. The SAXS peaks are characteristic for
a hexagonally ordered array of pores with a cell unit size of
9.9 nm. The FE-SEM and HRTEM analyses show a mixture
of homogenous cylindrical particles ~ 1 µm in length and
400 nm in diameter. Apart from the mesopores, SBA-15
might contain micropores in the pore walls (< 2 nm wide) [63].
SBA-15 could address many of the shortcomings of current
nanoparticle candidates. The key attributes that make
SBA-15 a compelling nanoparticle candidate for therapeutic
delivery can be classified into two categories: the external
surface or extra-particle properties, and the mesopore or
intra-particle properties. As the surface of SBA-15 is easily
functionalised, selective ligand-based interactions can be
mediated and targeting groups can be attached [43,64]. Particle
size and shape uniformity can also be addressed by properly
tuning the SBA-15 synthesis procedure to ensure that the
particles interact uniformly with the environment. Shapes
such as rods, spheres and platelet-like geometries can be
selected to mediate the desired physiological response [57,59].
Undesired interactions due to high-surface charge, as observed
in many other candidate materials, are addressed by the natu-
rally weak electrostatic surface charge of the SBA-15 particles,
which can be further modulated with surface functionalisa-
tion [53,43]. The covalent bonds of the SBA-15 framework
are stable, ensuring the persistence of the particles under
physiological conditions [51]. However, it is essential to note
that after incubation in simulated physiological fluid for
60 days, silica lixiviation from SBA-15 does occur and results
in partial loss of mesostructure. The loss of mesostructure due
to lixiviation, however, can be significantly reduced by surface
functionalisation. All of the basic geometric properties of
SBA-15 can be tuned to varying degrees during the synthesis
process [57,58], and the surface chemistry can be completely
customised using silane chemistry [43]. The particles have a
rigid structure that protects the integrity of the internal poros-
ity and can also be independently functionalised, separately
from the internal pore surface. This allows for the adjustment
of external surface properties to address issues of targeted
delivery and biocompatibility, such as the reduction of
particle aggregation in physiological environments.
Internally, the properties of the SBA-15 mesopores govern
the particle--therapeutic interactions. The narrow, uniformly
sized mesopores ensure that all of the protein cargo interacts
identically with the pore surface. In addition, the protein cargo
is only exposed to a constant, concave curvature, which has
been shown to have dramatic stabilising effects [10]. The pores
also provide direct physical protection from external hazards
such as proteases due to the rigid structure of SBA-15. The
weakly charged internal surface can be selectively functional-
ised, independently from the external surface, allowing for
controlled release and enhanced stability of protein cargo.
Figure 2 presents an overview of how SBA-15 can address the
intra- and extra-particle design constraints.
5. SBA-15 as a carrier of biological
therapeutics
Current research on the use of SBA-15 for therapeutics has
followed two main avenues: the fundamental understanding
J. Siefker et al.
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.and handling of the material, and specific applications,
primarily using non-biological therapeutics. Although the
use of SBA-15 for non-biological therapeutics is beyond the
scope of this article, some of the research will be reviewed as
it demonstrates methods and possible applications that could
be expanded to biological therapeutics. First, we will discuss
fundamental aspects of pore curvature and isolation effects [10].
Then, we will transition to the application of material tuning
and functionalisation to affect biological interactions [43,64],
and controlled release [65,66].
As discussed previously, SBA-15 contains hexagonally
ordered cylindrical mesopores with a narrow pore size distri-
bution. Compared with most other mesoporous silicas, this
gives it the unique ability to expose the biological cargo to
only concave curvature upon adsorption. This property of
SBA-15 was recently investigated by Sang et al. using myoglo-
bin and lysozyme as model proteins [10]. Sang et al. adsorbed
the model proteins onto SBA-15 of varying pore diameter
with both propylated and non-functionalised surface chemis-
tries, and then quantified the changes in catalytic activity and
secondary structure (via FTIR). The authors found that the
model proteins adsorbed on the propylated surface were less
catalytically active and had significant changes to their sec-
ondary structure when compared with the same proteins free
in solution. The changes in secondary structure showed no
dependence on the diameter of the pore. These results suggest
0123
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Figure 1. Characterisation of SBA-15. Illustration of a typical combination of methods used for the characterisation of SBA-15.
The key results of each analysis are included with each example. (A) FE-SEM and HRTEM (far right), (B) SAXS, (C)N 2
adsorption/desorption analysis.
FE-SEM: Field emission scanning electron microscopy; HRTEM: High-resolution transmission electron microscopy; SBA-15: Santa Barbara Amorphous-15;
SAXS: Small-angle x-ray scattering.
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.that a phase inversion and denaturing occurs on a hydropho-
bic interface, as one might suspect [10], and that pore curvature
does not play a dominant role in this system. In contrast, the
model proteins adsorbed on the non-functionalised, hydro-
philic surface show extraordinary increases in activity, and a
secondary structural dependence on pore diameter. As the
pore diameter decreases to approximately that of the size of
the model proteins, the secondary structure of the proteins
approach that of the free protein in solution. This trend
provides insight into the fundamental behaviour of confined
protein and demonstrates that pore curvature can play a
significant role in porous environments.
In trying to understand why this effect is so dramatic, one
can look at a structural analogue found in nature, the
GroEL/ES chaperonin complex. The GroEL/ES chaperonin
complex is required to finish the proper folding and for the
refolding of some misfolded bacterial proteins [67]. The
complex uses ATP to partially unfold or destabilise a protein,
and then facilitates the proper refolding via a kinetically medi-
ated minimisation of free energy [67]. The relevance of this
example becomes much more apparent once the structure of
SBA-15 and the GroEL/ES chaperonin complex are com-
pared. Both structures confine a protein in a hydrophilic,
cylindrical pore of approximately the same size as the protein
in which the surface is negatively charged [67]. This suggests
that there is something intrinsically fundamental to the con-
finement and curvature effects that are observed in this study,
which are different from other methods of immobilisation,
such as immobilisation on the surfaces of various nanopar-
ticles. In most nanoparticle systems, the observed effects are
attributed to an increase of convex curvature, which leads to
a minimisation of surface interactions [68], and, for catalysts,
an increased accessibility of the active site. The concave curva-
ture of the pores of SBA-15 dramatically increases the surface--
protein interaction. Associated stabilisation effects observed
by Sang et al. were observed as a corresponding increase in
protein activity. Also using activity as a gauge for stability,
Radhakrishna et al. [69] found that immobilisation on the
internal surface of SBA-15 increases the activity and stability
of alcohol dehydrogenase. Using computational methods it
was determined that the elimination of possible open-chain
conformations provides entropic effects enhancing the
observed increased stabilisation.
Although these results are promising, they merely imply
that stabilisation effects are present. To further demonstrate
the protection effects, Lynch et al. [70] investigated the protec-
tion effects rendered by SBA-15 to adsorbed myoglobin in the
presence of extreme pH and active protease. Their results
directly show that both pH and proteolytic protection effects
are present in both high-hydration and high-substrate envi-
ronments. The results show that confinement decreases the
activity of myoglobin at the optimum pH for the free-state
protein, although the results also show that confinement
induces a broadening in the range of myoglobin activity,
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Figure 2. Intra- and extra-particle aspects of SBA-15. Design aspects of SBA-15 are illustrated, highlighting their possible
application to address intra- and extra-particle challenges.
SBA-15: Santa Barbara Amorphous-15.
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.and that the resulting activity of the confined myoglobin is
much more consistent over the active pH range. This can be
seen as a significant advantage of using confined proteins. In
practice, the physiological environment in which a therapeutic
must operate cannot always be controlled and can also vastly
fluctuate [45,46]. The observed broadening and stabilisation
of the activity of the confined protein individually addresses
each of these issues and allows for a more robust and predict-
able activity of the resulting therapeutic. This, coupled with
the observed proteolytic protection effects, demonstrates the
stability and protection effects afforded by the curvature of
the SBA-15 system and creates an avenue for therapeutic
applications under physiologically challenging conditions.
Apart from pore curvature, other material properties, such
as the particle size, mesopore length and particle shape of
SBA-15, can also be modulated or tuned to achieve the desired
effect.Forexample,bychanging thesynthesisprocess,Zuetal.
achieved nearly 100% platelet-like particles [59] by varying the
duration and stirring speed during micellisation of the P123
template solution. The synthesis of platelet-like particles was
optimised for a micellisation time of 1 h with a stirring speed
between 800 and 1000 rpm. The particles resulting from this
process are ~ 400 nm long and 1000 nm in diameter. This cre-
ates a particle with an inverted aspect ratio as compared with
the more common rod-like particles. Also, as the mesopores
are aligned along the length of the particle; this morphology
reduces the length of the internal mesopores. Depending on
the desired application of the particles and how the platelet-
like particles can be made, the shortening of the pore length
could provide benefits, such as a quicker release of therapeutics
at the target site or as another tuning parameter to achieve
desired control release dynamics. It should be noted that this
method achieves a controlled change in particle morphology
without the addition of co-condensates or other structure-
directingagents [58,71].Thismethodleavestheremainingprop-
erties of SBA-15 intact and allows for the particle aspect ratio
and mesopore length to be varied independently from other
therapeutic design parameters. It is also possible to synthesise
spherical SBA-15 particles using alternative methods [72].
Similarly to the platelet-like particles, these particles maintain
the same properties as the rod-like SBA-15, except that the
particles are spherical and range in size from ~ 3t o
10 µm [72]. These particles also allow for the particle size and
mesopore length to be varied independently from other thera-
peutic design parameters. Prior studies have shown a strong
correlation between particle shape and their clearance by
phagocytes [25], thus allowing for design of stealth delivery sys-
tems or delivery systems that target a specific population of
immune cells.
Another design parameter that allows for significant modu-
lation of the particle properties is surface functionalisation.
The functionalisation of silica surfaces is well established; this
imparts flexibility and reliability on modifying the surface
chemistry of SBA-15. In addition, due to the stability of silane
bonds, after initial silica functionalisation, well-known organic
methods can be used to complete the process using click
chemistry [65,73-75]. This ensures the robustness of the surface
functionalisation process as any organically conjugated mole-
cule can be used. Further advances in the functionalisation of
porous silica, as discussed by Fryxell et al. [43], allow for very
high-density coverage of functional groups, severely limiting
accessibility of any unmodified surface from solution-borne
ions. This ensures full control over the surface properties of
SBA-15 [43]. A representative example of this method was
carriedoutbyPopovaetal. [65],resultinginacarboxyfunction-
alised surface. This method initially uses 3-amino-
propyltriethoxysilane to functionalise the silica surface using
silane chemistry with amino groups and then uses succinic
anhydride to react with the amine groups in an anhydrous
environment to produce carboxyl functional groups. Note
that this method follows the principal idea discussed above,
that is, the coupling of silane chemistry followed by organic
reaction. This study found that the carboxy functionalisation
increases the duration of sulfadiazine release without any
change of particle in vitro cytotoxicity in the Caco-2 cell line.
Similarly, Ahmadi et al. found that amino functionalisation
of SBA-15 significantly increases loading and release duration
of ibuprofen [76]. The latter increases from 2 h, releasing only
60% of the loaded therapeutic, to 200 h, releasing 95% of
the loaded therapeutic. This kind of behaviour is also seen
with low-solubility therapeutics. Mellaerts et al. found that
high hydroxylation of the SBA-15 surface increases the already
enhanced release of the poorly soluble therapeutic itraconazole
into a simulated biological fluid [77]. The release creates a
supersaturatedsolutionofitraconazoleandhasallowedformu-
lations for enteral administration to be demonstrated using
in vivo models [14].
Just as internal surface functionalisation of SBA-15 has
been used to control the internal environment of SBA-15,
external surface functionalisation is also used to directly
address the extra-particle challenge of targeted delivery. This
allows for the possibility of limiting therapeutic activity to
specific areas and targets such as the blood--brain barrier [78,79],
cancerous tissues [64,80], vasculature [81], adipose tissue [82,83],
and so on, due to inherent physiological properties and local
receptors. Pang et al. investigated the targeting of HeLa and
A549 cancer cells mediated by the folic acid receptor [64].
This was accomplished by monitoring folic acid conjugated
poly(ethylene imine) modified SBA-15 particles loaded with
doxorubicin hydrochloride by fluorescence microscopy and
flow cytometry. The conjugated particles showed lower cyto-
toxicity and much greater inhibition of the cancer cells than
the non-conjugated particles. The particles also demonstrated
sustained release behaviour that is typically desired with this
class of therapeutics.
Controlled release of therapeutic cargo can also be regulated
by methods other than just the general surface properties,
which can yield even greater design flexibility [84,85].O f
these methods, active pore capping [66,86], adaptive poly-
mers [87] and supramolecular assemblies [88] are currently
Packaging biological cargoes in mesoporous materials
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.showing great potential. Xue et al. [66] have demonstrated
controlled release by using lysozyme as a reversible pH respon-
sive nanovalve on mesoporous silica Mobil Composition of
Matter-41 (MCM-41). Like SBA-15, MCM-41 is synthesised
by macromolecular templating and contains a hexagonally
ordered array of mesopores [89]. The template is a cationic,
rather than a non-ionic surfactant, namely, cetyltrimethylam-
monium bromide. The pore walls, however, are thinner and
therefore less stable than in SBA-15, and the pore diameter is
typically smaller (~ 1.5 -- 10 nm) [90,91]. Controlled release
was accomplished even without functionalisation; however,
with functionalisation, much more elaborate mechanisms are
possible. Xue et al. have synthesised organic supramolecule
megagates that cap the pores of SBA-15 until exposed to a
pH below 5 [88]. These gates have the ability to regulate pores
of up to 6.5 nm in diameter and provide yet another tool for
SBA-15-based therapeutic development.
Although the insights and tools developed in each of these
studies do not separately give way to the next super-drug
delivery platform, the nature of the tools and the ability to
integrate them leads to many design possibilities. Stability
and protection effects from the physiological environment
are rendered by the fundamental effects of confinement,
curvature and pore surface properties. Targeted delivery and
physiological interactions are addressed by flexible external
surface functionalisation techniques that allow for a wide
range of functional groups. Controlled release is realised by
adaptive capping and functionalisation methods that are gov-
erned by processes ranging from simple conformational
changes to elaborate supramolecular interactions. Figure 2
summarises how the design tools of SBA-15 can be applied
to address challenges in the delivery of biological therapeutics.
Although this review by no means addresses all of the possible
challenges in the delivery of biologics, these tools provide
a compelling argument that supports the development of
SBA-15 as a serious component in the design of biological
therapeutics.
6. Expert opinion and future directions
Numerous tools are being developed for the delivery of
biological therapeutics. However, many of these tools require
the direct modification of the active biologic of interest [92].
This approach can be disadvantageous as it is specific to the
active biologic [93] and may require additional information
about protein stability and amino acid residues. This
approach can also decrease molecular stability, reduce bioac-
tivity, promote undesirable biological interactions including
aggregation and association with other proteins, and require
significantly different methods of modification for different
biological therapeutics. In using SBA-15 as a platform for
delivery, the delivery carrier is inherently separated from the
active biologic. This makes the platform universal and allows
for its application, independently of the desired methods of
discovery [94,95] and development [96].
One of the prominent challenges in the delivery of
biological therapeutics is that of protein crowding. The diffi-
culties arise at high protein concentrations, for which, in addi-
tion to destabilising protein--protein interactions, therapeutic
biologics can become too viscous to deliver via injection due
to gelation [97]. With targeted delivery, even if the protein
concentration in the formulated product is low, the resultant
local therapeutic concentration at the target site can still be
high. Although this is one of the motivations of targeted deliv-
ery that can be used to increase the effectiveness of treatment,
it can also lead to complications, which include the instability
of the therapeutic. Borwankar et al. have been able to prevent
gelation at very high protein concentrations through the use
of trehalose as a crowding agent [97]. This causes the formation
of a stable dispersion of protein nanoclusters that do not gel.
Although this addresses protein concentration during deliv-
ery, it does not address issues such as targeted delivery and
target site behaviour. Alternatively, confinement inside a
particle such as SBA-15 does address these issues, in addition
to countering gelation at high therapeutic concentrations. The
latter is achieved through modulation of the mesopore prop-
erties, although targeted delivery and site behaviour is realised
by functionalising the external surface of the particle. This
allows for a locally high concentration of the therapeutic at
the target site without the need for a permanent matrix or
the re-engineering of the active biologic [39]. This highlights
that, when using the SBA-15 platform, direct modification
of the intended therapeutic is not required.
As a consequence, the challenge in implementing the
SBA-15 platform lies in the particle design. This revolves
around particle biocompatibility and the tunability of both
the internal and the external material properties. Although
the biocompatibility of this platform is crucial for its success
as a therapeutic delivery system, the topic is too broad to be
thoroughly considered here. However, three studies are
discussed to highlight the work in this area showing the chal-
lenges associated with various routes of administration, parti-
cle sizes and particle concentrations [98,99]. Hudson et al.
evaluated the biocompatibility of mesoporous silicas with
particle sizes of 150 nm, 800 nm and 4 µm (MCM-41,
SBA-15 and mesocellular foam [MCF]) with pore sizes of 3,
7 and 16 nm, respectively. Subcutaneous injection of the
materials were well tolerated in a rat model and resulted in
elimination of the material progressively over 3 months while
showing good biocompatibility on histology. However, the
silicates were also shown to have a significant degree of toxic-
ity to mesothelial cells and resulted in death or euthanasia
when administered via intraperitoneal or intravenous injec-
tion to SV129 mice. On the other hand, Lu et al., using a
nude mice model, showed that fluorescent mesoporous silica
nanoparticles of 130 nm with 2 nm pores are well tolerated
via intraperitoneal and intravenous administration [100].
Lu et al. have also shown that almost all of the injected
particles are excreted via urine and feces within 4 days of
administration. Huang et al. conducted an in vivo study on
J. Siefker et al.
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.the effect of mesoporous silica nanoparticles on nude mice
xenografted with human malignant melanoma cells (A375)
[101]. Surprisingly, the nanoparticles led to an increase in
tumour growth. Follow-up in vitro studies confirmed that
the nanoparticles promoted cellular proliferation and acceler-
ated cell cycle progression of the tumour cells. Furthermore,
Huang et al. determined that these effects are due to a decreas-
ing of endogenous reactive oxygen species. These three seem-
ingly conflicting studies emphasise contradictory views on the
biocompatibility of these materials, and more importantly the
fact that the flexibility of the SBA-15 platform is essential for
its successful implementation. Size, shape, porosity and sur-
face chemistry are all important, and the ability to control
them in SBA-15 is crucial for successful biocompatible design
using this platform. This flexibility in design allows for the
accurate tuning of many material properties, including surface
functionalisation. The difficulty with most current methods is
that they impact the functionalisation of the whole, internal
and external, surface of SBA-15 particles. This leaves gaps in
the literature when selective functionalisation of the internal
and external surface is desired. Although methods do exist
[102-105], further development in selective functionalisation
and the fundamental behaviour of various chemistries would
significantly assist in the design of this class of biological
therapeutics. Additionally, the inherent design constraints of
SBA-15 need to be expanded. Although literature has shown
that SBA-15 can be synthesised with pore diameters that are
even larger than 30 nm, the larger the pore diameter the less
structured the particles become [106]. As many of the beneficial
properties of SBA-15 are directly linked to its pore structure
and narrow pore size distribution, better methods to synthe-
sise stable, well-structured SBA-15 with larger pore diameters
are needed. Also other nanostructured mesoporous materials
could be used with different three-dimensional pore topolo-
gies, such as SBA-16 [107], FDU-12 [108] and even MCF
[109]. However, these may not present the same consistent
concave curvature imparted by the cylindrical pores of
SBA-15.
Addressing these challenges will enable the rational
modulation of both the thermodynamic and kinetic aspects
of therapeutic delivery. This can range from designing a
strong thermodynamic driving force for protein desorption
from the particle, while creating a kinetic barrier to prevent
delivery until located at the targeted site (design 1), to
Design 1
Controlled release to target site
Receptor-mediated transcytosis
Enhanced biocompatibility
Assisted elimination of
therapeutic carrier
Modulation of residence time
Compartmentalization to the
vasculature
Compartmentalization to the
GI tract
Protection of therapeutic
during transit to target site
Protection from extreme pH
and proteases
Enhanced enzymatic activity
Increased environmental
tolerance
Design 2
Intravenous administration 1 Enteral administration 9
11
12
13
14
Elimination of therapeutic 15
10 2
3
4
5
6
7
Elimination of therapeutic 8
Intra-particle
Extra-particle
Intra-particle
Extra-particle
9
3
5
2
1 6
4
8 7
10
11
13
12 14
15
Figure 3. Overview of potential benefits of discussed therapeutic design cases. Benefits rendered by the intra- and
extra-particle properties of SBA-15 for each of the hypothetical therapeutic delivery designs discussed.
Reproduced with permission
  2014 Virginia E. Fulford.
SBA-15: Santa Barbara Amorphous-15.
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.optimising the internal pore structure for stability and activ-
ity, and the pore size for quick substrate diffusion (design 2).
A possible application of the first hypothetical design
would be the delivery of a biological therapeutic across the
blood--brain barrier. This could be achieved by the selective
functionalisation of the exterior surface of the particle with
appropriate ligands and biocompatibility coating. In this
case, the ligands could be a ‘marker of self’ peptide resembling
CD47 [81,110], and a transferrin recognition peptide [78]. The
‘marker of self’ peptide could act to prevent macrophage-
mediated clearance from the vasculature post-injection. This
would then allow the transferrin recognition peptide to bind
the particle to transferrin and facilitate the particle transfer
through the vascular endothelium via receptor-mediated
transcytosis. After transport across the blood--brain barrier,
the therapeutic could then benefit from enhanced desorption
from the particle.
In the second design, pore structure and size could be
optimised to increase stabilisation of the protein cargo as
well as the substrate diffusion rate to the catalytic protein ther-
apeutic. This would increase the effectiveness of the protein
used as the catalytic therapeutic. One application could be
the confinement of lactase to address lactose intolerance.
The stabilisation and protection effects due to confinement
would protect the therapeutic when exposed to the extreme
environments of the gastrointestinal tract. Particle size and
external functionalisation could then prevent the particle
from leaving the gastrointestinal tract and select for the
desired residence time of the therapeutic particle. An overview
of each of these designs can be seen in Figure 3.
Each of these examples illustrates the variability of applica-
tion without the requirement to modify the intended active
therapeutic. This along with the inherent stability effects
due to confinement and flexibility in design are the major
strengths of the SBA-15 platform.
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